Adopting new technologies for cervical cancer prevention
•Download as PPTX, PDF•
0 likes•50 views
This document discusses new technologies for cervical cancer prevention, including HPV vaccination, HPV testing, and cytology. HPV vaccination provides nearly 100% protection from cervical cancer if 70% of women are vaccinated. HPV testing is a more sensitive screening method than cytology or visual inspection with acetic acid and can identify women at risk of cervical disease earlier for treatment. The benefits of HPV testing include detecting existing HPV infections, identifying women at higher risk of cervical cancer, and providing longer-term protection compared to cytology alone. Widespread use of HPV vaccination and improved screening technologies like HPV testing can help reduce cervical cancer cases and deaths.
Report
Share
Report
Share
Recommended
Hpv vaccination gpsnew
HPV vaccination can prevent 70% of cervical cancers by targeting HPV types 16 and 18. While effective, vaccination will not eliminate cervical cancer risk since 30% of cancers are caused by other HPV types. Ongoing screening will still be needed for vaccinated women to address these remaining risks. Models show that vaccinating girls at age 12 combined with ongoing screening could reduce cervical cancers by 90% but is very costly. Catch up vaccination of older girls and boys provides only marginal benefits but at a much higher cost per life saved. Overall, HPV vaccination has great potential to reduce cervical cancer if provided before sexual debut, but screening must continue and vaccination programs must be implemented cost-effectively.
Future cervical screening program
The document discusses changes to the National Cervical Screening Program in Australia beginning in May 2017. Key changes include replacing the Pap smear with an HPV test as the primary screening, increasing the screening interval to 5 years, and expanding the age range screened to include women ages 25-74. The goal of the changes is to make cervical cancer screening safer, more effective, and more cost-effective by reducing unnecessary tests and follow-ups through a more targeted approach focused on HPV testing.
Hpv vaccination
HPV vaccination provides protection against HPV strains that cause cervical cancer and genital warts. The FDA has approved several HPV vaccines, including a quadrivalent vaccine protecting against strains 16, 18, 6, and 11, and a bivalent vaccine protecting against 16 and 18. Vaccination is recommended between ages 9-14 with a two dose schedule, or ages 15 and older with a three dose schedule. HPV vaccination has been shown to be safe and effective with common side effects being mild local reactions. Screening is still recommended for vaccinated individuals as the vaccines do not protect against all cancer-causing HPV strains.
Brenda kwambana adams
This document discusses optimal schedules for controlling pneumococcal infection in countries with high and low carriage. It notes that the African Meningitis Belt has seen sub-optimal pneumococcal conjugate vaccine (PCV) coverage due to geopolitical factors and vulnerable populations. Outbreaks in Ghana pre- and post-PCV introduction show that herd protection may be inadequate. Research is needed to better understand pneumococcal biology and prevention. Improving PCV access and coverage, including schedules with boosters and catch-up campaigns targeting 5-29 year olds, may help prevent outbreaks. Strengthening surveillance systems allows rapid response.
Dr Caroline trotter
This document discusses considerations for determining which age groups should be targeted for mass meningococcal vaccination campaigns. It notes that conjugate vaccines provide both direct and indirect (herd) protection if the age groups driving transmission are included. Models can simulate different options, like changes to UK MenC schedules or long-term strategies for MenAfriVac. Good age-specific data is needed on disease risk and carriage prevalence to identify peak transmitters. Campaigns targeting ages 1-29 years or compressing to 1-14 years are options, but more modeling is required to evaluate different approaches. Geographic risk must also be considered when expanding meningococcal programs.
Professor Nelesh govender
Cryptococcal meningitis is responsible for 15% of AIDS-related deaths globally. A strategic framework is needed to end cryptococcal meningitis deaths by 2030 by addressing gaps in screening, diagnosis, and access to critical antifungal medicines. Key targets include expanding access to CD4 and cryptococcal antigen tests, improving availability of lumbar puncture and antifungal drugs, and increasing research to develop better diagnostics and treatments.
Cervical Vaccines in India - Recent Updates, Gardasil Jalandhar feb 2017
1) A large study in India found that two doses of the HPV vaccine, administered 6 months apart, were as effective at preventing HPV infection as three doses in girls aged 10-18 years.
2) The two-dose schedule produced similar antibody levels and no cases of persistent infection with HPV types 16 and 18 were found over an average follow up of 4.7 years.
3) Based on these results, the study supports the WHO recommendation of a two-dose schedule of the HPV vaccine for young girls.
Professor Cal MacLennan
Gonorrhea is a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae that can lead to serious health complications if left untreated. There is an urgent need for a gonorrhea vaccine due to increasing antibiotic resistance and the potential for the disease to become untreatable. However, vaccine development faces several difficulties as N. gonorrhoeae is highly variable, able to avoid the immune system, and past vaccine trials have shown no efficacy. Continued research is focused on identifying conserved antigens that could induce a protective immune response through vaccination.
Recommended
Hpv vaccination gpsnew
HPV vaccination can prevent 70% of cervical cancers by targeting HPV types 16 and 18. While effective, vaccination will not eliminate cervical cancer risk since 30% of cancers are caused by other HPV types. Ongoing screening will still be needed for vaccinated women to address these remaining risks. Models show that vaccinating girls at age 12 combined with ongoing screening could reduce cervical cancers by 90% but is very costly. Catch up vaccination of older girls and boys provides only marginal benefits but at a much higher cost per life saved. Overall, HPV vaccination has great potential to reduce cervical cancer if provided before sexual debut, but screening must continue and vaccination programs must be implemented cost-effectively.
Future cervical screening program
The document discusses changes to the National Cervical Screening Program in Australia beginning in May 2017. Key changes include replacing the Pap smear with an HPV test as the primary screening, increasing the screening interval to 5 years, and expanding the age range screened to include women ages 25-74. The goal of the changes is to make cervical cancer screening safer, more effective, and more cost-effective by reducing unnecessary tests and follow-ups through a more targeted approach focused on HPV testing.
Hpv vaccination
HPV vaccination provides protection against HPV strains that cause cervical cancer and genital warts. The FDA has approved several HPV vaccines, including a quadrivalent vaccine protecting against strains 16, 18, 6, and 11, and a bivalent vaccine protecting against 16 and 18. Vaccination is recommended between ages 9-14 with a two dose schedule, or ages 15 and older with a three dose schedule. HPV vaccination has been shown to be safe and effective with common side effects being mild local reactions. Screening is still recommended for vaccinated individuals as the vaccines do not protect against all cancer-causing HPV strains.
Brenda kwambana adams
This document discusses optimal schedules for controlling pneumococcal infection in countries with high and low carriage. It notes that the African Meningitis Belt has seen sub-optimal pneumococcal conjugate vaccine (PCV) coverage due to geopolitical factors and vulnerable populations. Outbreaks in Ghana pre- and post-PCV introduction show that herd protection may be inadequate. Research is needed to better understand pneumococcal biology and prevention. Improving PCV access and coverage, including schedules with boosters and catch-up campaigns targeting 5-29 year olds, may help prevent outbreaks. Strengthening surveillance systems allows rapid response.
Dr Caroline trotter
This document discusses considerations for determining which age groups should be targeted for mass meningococcal vaccination campaigns. It notes that conjugate vaccines provide both direct and indirect (herd) protection if the age groups driving transmission are included. Models can simulate different options, like changes to UK MenC schedules or long-term strategies for MenAfriVac. Good age-specific data is needed on disease risk and carriage prevalence to identify peak transmitters. Campaigns targeting ages 1-29 years or compressing to 1-14 years are options, but more modeling is required to evaluate different approaches. Geographic risk must also be considered when expanding meningococcal programs.
Professor Nelesh govender
Cryptococcal meningitis is responsible for 15% of AIDS-related deaths globally. A strategic framework is needed to end cryptococcal meningitis deaths by 2030 by addressing gaps in screening, diagnosis, and access to critical antifungal medicines. Key targets include expanding access to CD4 and cryptococcal antigen tests, improving availability of lumbar puncture and antifungal drugs, and increasing research to develop better diagnostics and treatments.
Cervical Vaccines in India - Recent Updates, Gardasil Jalandhar feb 2017
1) A large study in India found that two doses of the HPV vaccine, administered 6 months apart, were as effective at preventing HPV infection as three doses in girls aged 10-18 years.
2) The two-dose schedule produced similar antibody levels and no cases of persistent infection with HPV types 16 and 18 were found over an average follow up of 4.7 years.
3) Based on these results, the study supports the WHO recommendation of a two-dose schedule of the HPV vaccine for young girls.
Professor Cal MacLennan
Gonorrhea is a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae that can lead to serious health complications if left untreated. There is an urgent need for a gonorrhea vaccine due to increasing antibiotic resistance and the potential for the disease to become untreatable. However, vaccine development faces several difficulties as N. gonorrhoeae is highly variable, able to avoid the immune system, and past vaccine trials have shown no efficacy. Continued research is focused on identifying conserved antigens that could induce a protective immune response through vaccination.
PATH Malaria Vaccine Initiative
MVI's mission is to accelerate malaria vaccine development and ensure availability in developing countries. Its goal is an 80% effective vaccine lasting 4+ years by 2025. Malaria infects 250 million people annually and kills 900,000, mostly children in Africa. Vaccine development faces challenges due to the parasite's complexity and limited commercial markets. MVI partners with organizations to systematically develop promising approaches through clinical trials. Its current strategy focuses on pre-erythrocytic, transmission-blocking, and P. vivax vaccines. With a phase 3 trial underway, MVI's public-private model brings malaria vaccines closer to reality.
Dr Sami gottlieb
Dr. Sami Gottlieb of the World Health Organization discussed the potential for meningococcal B (MenB) vaccines to help prevent gonococcal infection on a global scale. MenB vaccines have shown preliminary efficacy against gonorrhea in clinical trials and epidemiological data. WHO is working to define priority populations for gonorrhea vaccines and assess how existing MenB programs could be leveraged. Effectiveness may depend on disease epidemiology, vaccine characteristics, target populations, and integration with current immunization systems. Ongoing trials of MenB vaccines against gonorrhea will provide critical data to inform introduction decisions.
HPV related Gynecological Cancers
This document discusses HPV-related malignancies and summarizes several key points from various sources, including: the disease burden of HPV, prevalence and types of HPV, carcinogenesis process, cofactors influencing HPV disease, treatment approaches, prognostic factors, and opportunities for primary and secondary prevention. It notes that high-risk HPV infection after mucosal contact can lead to changes in cervical cells from normal to precancerous or cancerous. It also discusses the potential for second-generation HPV vaccines that have lower costs, require fewer doses, and provide protection against a broader range of HPV types to further reduce rates of cervical precancer and cancer globally.
Sara katz
natural immunity in the african meningitis belt to neisseria meningitidis serogroup x-a seroprevalence study
Dr Adam dale
1. Healthy adults were randomly assigned to receive an intranasal inoculation with either Neisseria lactamica (Nlac) or a placebo control. 2. Blood samples were collected to assess B cell responses specific to Nlac and the related pathogen Neisseria meningitidis (Nmen). 3. The study found that colonization with Nlac induced plasma cells that produced antibodies cross-reactive between Nlac and Nmen, suggesting Nlac colonization can stimulate immune memory against Nmen.
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
This document provides a summary of a presentation on prospects for developing a Group B Streptococcus (GBS) vaccine for pregnant women globally. It notes that GBS is a leading cause of neonatal infections and discusses the limitations of the current prevention strategy using intrapartum antibiotics. Developing a maternal GBS vaccine could have a higher impact by preventing more outcomes and providing more equitable coverage. Ongoing work includes further vaccine development and clinical trials, establishing a global disease burden, developing standardized assays to assess vaccine protection, and guidance for vaccine policy and implementation. The goal is to develop a safe and effective maternal GBS vaccine to reduce infant mortality from this disease worldwide.
Camilla gladstone
Identification of Neisseria meningitidis specific patient derived antibodies using reverse vaccinology 2 0
Prof Martin Antonio @ MRF's Meningitis and Septicaemia 2019
The document discusses invasive bacterial disease (IBD) surveillance in West and Central Africa conducted by the MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine. It summarizes that the unit oversees the largest IBD surveillance network in the region, monitoring the impact of pneumococcal conjugate vaccines. Analysis of surveillance data from 2010-2016 shows declines in pneumococcal meningitis cases and deaths following vaccine introduction, though impact varies by country. Continued surveillance is needed to fully assess the effects of vaccination programs.
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
Implications of epidemic pneumococcal meningitis in meningitis belt countries
https://www.meningitis.org/mrf-conference-2017Prof Rob Heyderman
The document discusses the Global Meningitis Genome Partnership (GMGP), which aims to address inequities in genomic surveillance capacity for meningitis pathogens between high-income and low-income countries. It outlines what has been achieved so far, including establishing standardized metadata for sequencing and epidemiological data. The GMGP is working to incorporate genome surveillance into regional surveillance strategies, initially focusing on Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus agalactiae in Africa. Open data sharing is encouraged according to clear governance policies. Standardizing metadata and curating sequencing data in a central library are discussed to facilitate consistent analysis and data visualization for public health benefit
Professor Stefan flasche
While pneumococcal disease primarily burdens infants in their first year of life, relying on herd effects from PCV schedules could help protect others indirectly and reduce costs. However, caution is needed, as indirect protection depends on direct protection of main transmitters, and key questions remain around who transmits, the duration of protection from boosters, and lessons from cRCTs comparing 2-dose and 3-dose schedules in Malawi and Gambia. Programmatic concerns like booster dose coverage, incomplete dosing, travel/border effects, and lack of surveillance also warrant consideration.
Dr Steve Gray @ MRF's Meningitis and Septicaemia 2019
This document summarizes the epidemiology and surveillance of meningococcal disease in England. It describes the mature surveillance system that has been in place since 1984 and involves cooperation between reference laboratories, epidemiologists, and immunization colleagues. The surveillance is supported by microbiology laboratories across England and Public Health England health protection teams. The comprehensive dataset collected allows for characterization of cultures and whole genome sequencing of invasive meningococcal disease cultures since 2010. The data show a rapid reduction in group C meningococcal disease following vaccination but an increase in group W disease since 2009. Surveillance is essential to monitor changes in meningococcal populations, support vaccine development and evaluation, and modify immunization schedules.
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
1. A MenACWY vaccination program was introduced in England starting in 2015 to address a rise in MenW cases since 2009, targeting teenagers ages 14-18 and university freshers.
2. Rollout of the program presented challenges including a short timeframe and difficulty motivating older teenagers. Coverage rates were lower in older age groups.
3. Early data indicates the program has been successful, with a 69% reduction in MenW cases in the first targeted group and falls in cases ages 15-24 and under 1 year old. University associated cases also decreased.Medical care of
This document discusses treatment guidelines for Providencia infections. Providencia stuartii is typically the most resistant species and carbapenems are the recommended empirical treatment for life-threatening P. stuartii infections until identification and susceptibility testing can be done. P. alcalifaciens and P. rustigianii tend to be more susceptible to many antibiotics. Treatment should be narrowed once susceptibility is known and last 1-3 weeks depending on the infection site. Indwelling devices should be removed if associated with the infection.
Dr Muhamed-Kheir Taha @ MRF's Meningitis and Septicaemia 2019
1) The document discusses new complement inhibitor drugs and their implications for clinical practice and vaccination policy. It reviews complement activation pathways and deficiencies.
2) Patients receiving complement inhibitor treatments like eculizumab are at higher risk for invasive meningococcal disease due to vaccine failures or non-vaccine serogroup infections. One case study showed IMD from a vaccine-targeted but penicillin-resistant strain in a patient on eculizumab.
3) The document recommends vaccination against meningococcal serogroups A, C, W, and Y for those with complement deficiencies from inherited or acquired causes like treatment. It also suggests continuing antibiotic prophylaxis and planning for self-treatment rescue antibiotics
Yangyupei yang
1) The PSERENADE project analyzed surveillance data from over 50 sites in 34 countries to assess the impact of PCV10 and PCV13 introduction on pneumococcal meningitis incidence globally in children under 5 years old and adults 18 years and older.
2) For both age groups, PCV10 and PCV13 significantly reduced meningitis caused by serotypes covered by the vaccines, with almost elimination in children under 5 years old within 5 years. Herd protection was observed in adults as well.
3) PCV13 significantly reduced meningitis from additional serotypes it covers compared to PCV10, though serotype 19A increased with PCV10 and serotype 3 trends were unclear
Meningitis Research Foundation' current and upcoming work by Linda Glennie
Meningitis Research Foundation' current and upcoming work by Linda GlennieMeningitis Research Foundation
The document discusses the Meningitis Research Foundation's current and upcoming work including assessing the impact of meningitis on families, developing a comprehensive meningococcal genome library, estimating the true burden of meningococcal disease in England, and funding 17 current research projects totaling over £2.7 million. It also puts out a call for proposals on hot topics in meningococcal research like monitoring MenB vaccine implementation and developing improved second generation MenB vaccines.Scientific Sessions 2015: STI diagnosis among msm
Scientific Sessions 2015: STI diagnosis among msmSri Lanka College of Sexual Health and HIV Medicine
This document discusses STI diagnosis and screening recommendations for men who have sex with men (MSM). It finds that MSM are at higher risk for STIs like HIV, syphilis, gonorrhea and chlamydia. STIs are often asymptomatic in MSM, especially for rectal and pharyngeal infections. NAAT tests are highly sensitive for detection but have limitations. The WHO and CDC recommend regular STI screening for sexually active MSM, including annual HIV, syphilis, urethral and rectal gonorrhea/chlamydia testing using NAATs.Dr Matt Coldiron @ MRF's Meningitis and Septicaemia
Debate - Adjunctive corticosteroids for acute bacterial meningitis in Africa - do we need more evidence?
PARASITIC INFECTIONS ...
1) The document discusses the need for better diagnostic approaches for parasitic infections. Traditional diagnostic methods have changed little in over a century and cannot distinguish between different stages of infection or response to treatment.
2) While new technologies like PCR and ELISA have improved diagnosis, many facilities still lack resources and trained technicians to utilize advanced methods. Reliance on microscopy remains common but is time-consuming and requires skill.
3) The author argues that improving diagnostic capabilities for parasitic diseases through incorporating new technologies and training more experts could help reduce antibiotic overprescription and emergence of drug resistance.
Hpv vaccine
HPV (human papillomavirus) is extremely common, with 80% of sexually active people contracting a strain at some point. It causes various cancers and genital warts. While most HPV infections clear on their own, persistent infections increase cancer risk. Vaccines target high-risk HPV strains responsible for 70% of cervical cancers. They provide sustained, high-level immunity for at least 4.5 years with minimal side effects. Screening and vaccination can significantly reduce HPV-related cancers globally.
Road map to eliminate Cervical Cancer in the Indian subcontinent 2023 Dr V ...
Road map to eliminate Cervical Cancer in the Indian subcontinent 2023 Dr V ...Kidwai Memorial Institute of Oncology, Bangalore
Cervical cancer is a major problem worldwide and in India. HPV is the primary cause, with types 16 and 18 responsible for about 80% of cases globally. A large Swedish study found HPV vaccination reduced cervical cancer risk by 63% compared to unvaccinated women. WHO guidelines recommend girls-only HPV vaccination before age 9 along with twice-lifetime screening to accelerate global cervical cancer elimination between 2059 to 2102 and prevent an additional 12.1 million cases.More Related Content
What's hot
PATH Malaria Vaccine Initiative
MVI's mission is to accelerate malaria vaccine development and ensure availability in developing countries. Its goal is an 80% effective vaccine lasting 4+ years by 2025. Malaria infects 250 million people annually and kills 900,000, mostly children in Africa. Vaccine development faces challenges due to the parasite's complexity and limited commercial markets. MVI partners with organizations to systematically develop promising approaches through clinical trials. Its current strategy focuses on pre-erythrocytic, transmission-blocking, and P. vivax vaccines. With a phase 3 trial underway, MVI's public-private model brings malaria vaccines closer to reality.
Dr Sami gottlieb
Dr. Sami Gottlieb of the World Health Organization discussed the potential for meningococcal B (MenB) vaccines to help prevent gonococcal infection on a global scale. MenB vaccines have shown preliminary efficacy against gonorrhea in clinical trials and epidemiological data. WHO is working to define priority populations for gonorrhea vaccines and assess how existing MenB programs could be leveraged. Effectiveness may depend on disease epidemiology, vaccine characteristics, target populations, and integration with current immunization systems. Ongoing trials of MenB vaccines against gonorrhea will provide critical data to inform introduction decisions.
HPV related Gynecological Cancers
This document discusses HPV-related malignancies and summarizes several key points from various sources, including: the disease burden of HPV, prevalence and types of HPV, carcinogenesis process, cofactors influencing HPV disease, treatment approaches, prognostic factors, and opportunities for primary and secondary prevention. It notes that high-risk HPV infection after mucosal contact can lead to changes in cervical cells from normal to precancerous or cancerous. It also discusses the potential for second-generation HPV vaccines that have lower costs, require fewer doses, and provide protection against a broader range of HPV types to further reduce rates of cervical precancer and cancer globally.
Sara katz
natural immunity in the african meningitis belt to neisseria meningitidis serogroup x-a seroprevalence study
Dr Adam dale
1. Healthy adults were randomly assigned to receive an intranasal inoculation with either Neisseria lactamica (Nlac) or a placebo control. 2. Blood samples were collected to assess B cell responses specific to Nlac and the related pathogen Neisseria meningitidis (Nmen). 3. The study found that colonization with Nlac induced plasma cells that produced antibodies cross-reactive between Nlac and Nmen, suggesting Nlac colonization can stimulate immune memory against Nmen.
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
This document provides a summary of a presentation on prospects for developing a Group B Streptococcus (GBS) vaccine for pregnant women globally. It notes that GBS is a leading cause of neonatal infections and discusses the limitations of the current prevention strategy using intrapartum antibiotics. Developing a maternal GBS vaccine could have a higher impact by preventing more outcomes and providing more equitable coverage. Ongoing work includes further vaccine development and clinical trials, establishing a global disease burden, developing standardized assays to assess vaccine protection, and guidance for vaccine policy and implementation. The goal is to develop a safe and effective maternal GBS vaccine to reduce infant mortality from this disease worldwide.
Camilla gladstone
Identification of Neisseria meningitidis specific patient derived antibodies using reverse vaccinology 2 0
Prof Martin Antonio @ MRF's Meningitis and Septicaemia 2019
The document discusses invasive bacterial disease (IBD) surveillance in West and Central Africa conducted by the MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine. It summarizes that the unit oversees the largest IBD surveillance network in the region, monitoring the impact of pneumococcal conjugate vaccines. Analysis of surveillance data from 2010-2016 shows declines in pneumococcal meningitis cases and deaths following vaccine introduction, though impact varies by country. Continued surveillance is needed to fully assess the effects of vaccination programs.
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
Implications of epidemic pneumococcal meningitis in meningitis belt countries
https://www.meningitis.org/mrf-conference-2017Prof Rob Heyderman
The document discusses the Global Meningitis Genome Partnership (GMGP), which aims to address inequities in genomic surveillance capacity for meningitis pathogens between high-income and low-income countries. It outlines what has been achieved so far, including establishing standardized metadata for sequencing and epidemiological data. The GMGP is working to incorporate genome surveillance into regional surveillance strategies, initially focusing on Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus agalactiae in Africa. Open data sharing is encouraged according to clear governance policies. Standardizing metadata and curating sequencing data in a central library are discussed to facilitate consistent analysis and data visualization for public health benefit
Professor Stefan flasche
While pneumococcal disease primarily burdens infants in their first year of life, relying on herd effects from PCV schedules could help protect others indirectly and reduce costs. However, caution is needed, as indirect protection depends on direct protection of main transmitters, and key questions remain around who transmits, the duration of protection from boosters, and lessons from cRCTs comparing 2-dose and 3-dose schedules in Malawi and Gambia. Programmatic concerns like booster dose coverage, incomplete dosing, travel/border effects, and lack of surveillance also warrant consideration.
Dr Steve Gray @ MRF's Meningitis and Septicaemia 2019
This document summarizes the epidemiology and surveillance of meningococcal disease in England. It describes the mature surveillance system that has been in place since 1984 and involves cooperation between reference laboratories, epidemiologists, and immunization colleagues. The surveillance is supported by microbiology laboratories across England and Public Health England health protection teams. The comprehensive dataset collected allows for characterization of cultures and whole genome sequencing of invasive meningococcal disease cultures since 2010. The data show a rapid reduction in group C meningococcal disease following vaccination but an increase in group W disease since 2009. Surveillance is essential to monitor changes in meningococcal populations, support vaccine development and evaluation, and modify immunization schedules.
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
1. A MenACWY vaccination program was introduced in England starting in 2015 to address a rise in MenW cases since 2009, targeting teenagers ages 14-18 and university freshers.
2. Rollout of the program presented challenges including a short timeframe and difficulty motivating older teenagers. Coverage rates were lower in older age groups.
3. Early data indicates the program has been successful, with a 69% reduction in MenW cases in the first targeted group and falls in cases ages 15-24 and under 1 year old. University associated cases also decreased.Medical care of
This document discusses treatment guidelines for Providencia infections. Providencia stuartii is typically the most resistant species and carbapenems are the recommended empirical treatment for life-threatening P. stuartii infections until identification and susceptibility testing can be done. P. alcalifaciens and P. rustigianii tend to be more susceptible to many antibiotics. Treatment should be narrowed once susceptibility is known and last 1-3 weeks depending on the infection site. Indwelling devices should be removed if associated with the infection.
Dr Muhamed-Kheir Taha @ MRF's Meningitis and Septicaemia 2019
1) The document discusses new complement inhibitor drugs and their implications for clinical practice and vaccination policy. It reviews complement activation pathways and deficiencies.
2) Patients receiving complement inhibitor treatments like eculizumab are at higher risk for invasive meningococcal disease due to vaccine failures or non-vaccine serogroup infections. One case study showed IMD from a vaccine-targeted but penicillin-resistant strain in a patient on eculizumab.
3) The document recommends vaccination against meningococcal serogroups A, C, W, and Y for those with complement deficiencies from inherited or acquired causes like treatment. It also suggests continuing antibiotic prophylaxis and planning for self-treatment rescue antibiotics
Yangyupei yang
1) The PSERENADE project analyzed surveillance data from over 50 sites in 34 countries to assess the impact of PCV10 and PCV13 introduction on pneumococcal meningitis incidence globally in children under 5 years old and adults 18 years and older.
2) For both age groups, PCV10 and PCV13 significantly reduced meningitis caused by serotypes covered by the vaccines, with almost elimination in children under 5 years old within 5 years. Herd protection was observed in adults as well.
3) PCV13 significantly reduced meningitis from additional serotypes it covers compared to PCV10, though serotype 19A increased with PCV10 and serotype 3 trends were unclear
Meningitis Research Foundation' current and upcoming work by Linda Glennie
Meningitis Research Foundation' current and upcoming work by Linda GlennieMeningitis Research Foundation
The document discusses the Meningitis Research Foundation's current and upcoming work including assessing the impact of meningitis on families, developing a comprehensive meningococcal genome library, estimating the true burden of meningococcal disease in England, and funding 17 current research projects totaling over £2.7 million. It also puts out a call for proposals on hot topics in meningococcal research like monitoring MenB vaccine implementation and developing improved second generation MenB vaccines.Scientific Sessions 2015: STI diagnosis among msm
Scientific Sessions 2015: STI diagnosis among msmSri Lanka College of Sexual Health and HIV Medicine
This document discusses STI diagnosis and screening recommendations for men who have sex with men (MSM). It finds that MSM are at higher risk for STIs like HIV, syphilis, gonorrhea and chlamydia. STIs are often asymptomatic in MSM, especially for rectal and pharyngeal infections. NAAT tests are highly sensitive for detection but have limitations. The WHO and CDC recommend regular STI screening for sexually active MSM, including annual HIV, syphilis, urethral and rectal gonorrhea/chlamydia testing using NAATs.Dr Matt Coldiron @ MRF's Meningitis and Septicaemia
Debate - Adjunctive corticosteroids for acute bacterial meningitis in Africa - do we need more evidence?
PARASITIC INFECTIONS ...
1) The document discusses the need for better diagnostic approaches for parasitic infections. Traditional diagnostic methods have changed little in over a century and cannot distinguish between different stages of infection or response to treatment.
2) While new technologies like PCR and ELISA have improved diagnosis, many facilities still lack resources and trained technicians to utilize advanced methods. Reliance on microscopy remains common but is time-consuming and requires skill.
3) The author argues that improving diagnostic capabilities for parasitic diseases through incorporating new technologies and training more experts could help reduce antibiotic overprescription and emergence of drug resistance.
What's hot (20)
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
Prof Martin Antonio @ MRF's Meningitis and Septicaemia 2019
Prof Martin Antonio @ MRF's Meningitis and Septicaemia 2019
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Dr Steve Gray @ MRF's Meningitis and Septicaemia 2019
Dr Steve Gray @ MRF's Meningitis and Septicaemia 2019
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Dr Muhamed-Kheir Taha @ MRF's Meningitis and Septicaemia 2019
Dr Muhamed-Kheir Taha @ MRF's Meningitis and Septicaemia 2019
Meningitis Research Foundation' current and upcoming work by Linda Glennie
Meningitis Research Foundation' current and upcoming work by Linda Glennie
Dr Matt Coldiron @ MRF's Meningitis and Septicaemia
Dr Matt Coldiron @ MRF's Meningitis and Septicaemia
Similar to Adopting new technologies for cervical cancer prevention
Hpv vaccine
HPV (human papillomavirus) is extremely common, with 80% of sexually active people contracting a strain at some point. It causes various cancers and genital warts. While most HPV infections clear on their own, persistent infections increase cancer risk. Vaccines target high-risk HPV strains responsible for 70% of cervical cancers. They provide sustained, high-level immunity for at least 4.5 years with minimal side effects. Screening and vaccination can significantly reduce HPV-related cancers globally.
Road map to eliminate Cervical Cancer in the Indian subcontinent 2023 Dr V ...
Road map to eliminate Cervical Cancer in the Indian subcontinent 2023 Dr V ...Kidwai Memorial Institute of Oncology, Bangalore
Cervical cancer is a major problem worldwide and in India. HPV is the primary cause, with types 16 and 18 responsible for about 80% of cases globally. A large Swedish study found HPV vaccination reduced cervical cancer risk by 63% compared to unvaccinated women. WHO guidelines recommend girls-only HPV vaccination before age 9 along with twice-lifetime screening to accelerate global cervical cancer elimination between 2059 to 2102 and prevent an additional 12.1 million cases.Cervavac : A silver bullet for protection against cervical cancer : Dr Sharda...
The document discusses human papillomavirus (HPV) and cervical cancer. It provides details on HPV transmission, prevalence, and types. HPV is most commonly spread through sexual contact and can cause genital warts or cancers like cervical cancer. HPV types 16 and 18 cause the majority of cervical cancers globally and in India. The document advocates for HPV vaccination, especially in younger ages, as well as screening and treatment, to work towards eliminating cervical cancer as outlined by WHO goals. It discusses real-world data showing significant reductions in cervical cancers and precancers from HPV vaccination. India's first indigenous HPV vaccine, Cervavac, is also discussed.
Cervical Cancer
Cervical Cancer is common worldwide , ranking 3rd among all malignancies for women.
Second leading cause of cancer death.
Most of these cancers stem from infection with the Human Pappiloma Virus (HPV).
Pink october.pptx
The document discusses screening methods for cervical cancer prevention and control. It recommends vaccinating 90% of eligible girls against HPV, screening 70% of eligible women at least twice in their lifetime using Pap smear and HPV DNA testing, and effectively treating 90% of women with positive screening results by 2030. Pap smear collects cervical cells to detect early cancer cells, while HPV DNA testing detects high-risk HPV infection. Combining the two methods can achieve nearly 100% accuracy. Screening should stop at age 65 for women with consecutive negative results over 15 years or if no prior screening was done, one test is recommended before exiting the program. The Gardasil 9 vaccine prevents cervical, anal, and other cancers caused by 9 HPV
HPV and Cervical Cancer
Cervical cancer is a major health problem, but HPV vaccination and screening can reduce rates. HPV is transmitted sexually and can cause cervical cancer. The vaccine protects against high-risk HPV types 16 and 18, which cause most cancers. Northern Ireland has high HPV vaccination rates. While the vaccine reduces cancer risk, screening is still needed since the vaccine does not protect against all HPV types and cannot help women already infected. In the future, screening may shift to HPV testing as prevalence decreases due to vaccination.
CNE PRESENTATION.pptx
Cervical cancer is the fourth most common cancer in women globally, with over 600,000 new cases and 342,000 deaths estimated in 2020. It is caused by certain strains of the human papillomavirus (HPV), which are spread through sexual contact. The presentation discusses HPV vaccination and cervical cancer screening as primary and secondary prevention strategies. It recommends vaccinating girls ages 9-45 and screening eligible women twice in their lifetimes as targets to accelerate elimination of cervical cancer by 2030.
HPV INFECTIONS WITH RECENT ADVANCES IN CARCINOMA CERVIX.pptx
1) Cervical cancer is a major public health problem in India, which accounts for about 27% of new cervical cancer cases and deaths worldwide.
2) Screening through tests like visual inspection with acetic acid (VIA) and treatment of pre-cancerous lesions can prevent the majority of cervical cancers. Vaccination against HPV also provides protection.
3) Effective treatments for pre-cancerous lesions include cryotherapy, loop electrosurgical excision procedure (LEEP), and laser ablation, while early invasive cancers can be treated with surgery, radiotherapy, or chemotherapy.
Cervavac_Speaker_Set_1.pptx
This document discusses HPV, its link to cervical cancer, and CERVAVAC, an indigenous HPV vaccine developed in India. It provides background on HPV, noting it is the most common STI and can cause several cancers including cervical cancer. It explains how HPV evades the immune system and its lifecycle in the cervix. It classifies HPV types as high-risk or low-risk and notes that high-risk HPV 16 and 18 cause over 70% of cervical cancer cases globally. It discusses cervical cancer signs, symptoms and prevention methods like education, screening via Pap tests, and vaccination. It provides an overview of CERVAVAC, India's first indigenous HPV vaccine, and its goal of being affordable and
Recent updates in hpv vaccines
This document discusses cervical cancer and HPV in India. It notes that India accounts for 27% of new cervical cancer cases and deaths worldwide despite having only 16% of the global population. It is estimated that over 365 women will die from cervical cancer daily in India by 2025. HPV is the main cause of cervical cancer and certain HPV types are also associated with other cancers. The document discusses HPV vaccines as the primary prevention for HPV-related diseases and recommends routine vaccination of girls aged 9-12 years along with catch-up vaccination up to age 26. It provides details on the available HPV vaccines and their efficacy, safety and recommended dosage schedules.
CERVICAL CANCER presentation for the clinic
Cervical cancer is a leading cause of cancer deaths in women worldwide. It is caused by human papillomavirus (HPV) infection and can be prevented through HPV vaccination and screening. Early detection through tests like visual inspection with acetic acid helps detect pre-cancerous lesions early on so they can be treated before the cancer develops further. Treatment depends on the stage of cancer and may involve surgery, radiation therapy, or chemotherapy, with the goal of curing early-stage cancer or palliatively treating advanced stages.
Mission SAY No to Cervical Cancer With HPV Vaccination DR. SHARDA JAIN S...
1. Cervical cancer is a major health issue in India, accounting for 23% of new cervical cancer cases and 25% of cervical cancer deaths worldwide.
2. Human papillomavirus (HPV) infection causes cervical cancer, with vaccination providing 98-100% efficacy against HPV types.
3. Screening and vaccination can help prevent cervical cancer, but coverage in India remains low due to cost and lack of national programs.
Cervical cancer screening guidelines 2013 on 7th sept
The document summarizes the 2013 guidelines for cervical cancer screening in the United States. The key points are:
1. Screening should begin at age 21 with cytology alone every 3 years until age 30.
2. From ages 30-65, co-testing with cytology and HPV testing every 5 years is the preferred method. Cytology alone every 3 years is acceptable.
3. Screening can stop at age 65 for women with adequate negative prior screening and no history of CIN2 or worse. Screening after a hysterectomy also depends on whether the cervix was removed.
Cervical cancer Dr.Alia
Cervical cancer is a preventable disease ..
by awerrness about risk factors we can prevent it easily .
HPV Vaccination Update in 2021 Dr Sharda Jain
This document discusses the importance of prioritizing HPV vaccination in India. It notes that cervical cancer is a major problem in India, with over 60,000 deaths per year. However, HPV vaccination rates in India are less than 1%. The document advocates scaling up HPV vaccination programs for adolescent girls according to WHO guidelines. Vaccinating girls before age 15 is key to eliminating cervical cancer as a public health problem. It also discusses opportunities for catch-up vaccination by OBGYNs and nurses when women visit for other women's health issues. The overall message is that HPV vaccination should be a top priority for the Indian government to substantially reduce the cervical cancer burden.
AN OPPORTUNITY FOR HPV VACCINATION , Dr. Sharda Jain Lifecare Centre
This document discusses strategies for cervical cancer prevention in India through HPV vaccination. It notes that cervical cancer is almost entirely preventable but prevention efforts in India have been inadequate. HPV vaccination provides strong protection, especially if received before sexual debut. However, vaccination rates in India are very low. The document argues that the postpartum period provides an opportunity for catch-up HPV vaccination that can improve coverage. Several studies show high HPV prevalence in postpartum women, demonstrating the potential benefit. Other evidence suggests postpartum women are receptive to vaccination and compliance with the 3 dose schedule can be high with proper counseling. The document advocates that healthcare providers should recommend HPV vaccination to women in the postpartum period to help control cervical cancer in India
Cervical cancer screening guidelines 2013
The document summarizes the 2013 guidelines for cervical cancer screening in average-risk women. It recommends that screening should begin at age 21 with conventional or liquid-based cytology every 3 years. From ages 30-65, it is acceptable to continue cytology alone every 3 years, but preferred is co-testing with cytology and HPV testing every 5 years. Screening should stop at age 65 for women with adequate negative prior screening or after total hysterectomy with no history of precancerous lesions. The guidelines do not recommend annual screening or primary HPV testing alone for screening.
Screening for Female Genital Tract Malignancy
This document summarizes screening guidelines and methods for detecting female genital tract malignancies. It discusses screening criteria and validity, risk factors and epidemiology for cervical, endometrial, ovarian and vulvar cancers. Alternative screening methods to Pap smears like visual inspection with acetic acid and HPV testing are described. Guidelines are provided for breast, cervical and endometrial cancer screening intervals.
Similar to Adopting new technologies for cervical cancer prevention (20)
Road map to eliminate Cervical Cancer in the Indian subcontinent 2023 Dr V ...
Road map to eliminate Cervical Cancer in the Indian subcontinent 2023 Dr V ...
Cervavac : A silver bullet for protection against cervical cancer : Dr Sharda...
Cervavac : A silver bullet for protection against cervical cancer : Dr Sharda...
HPV INFECTIONS WITH RECENT ADVANCES IN CARCINOMA CERVIX.pptx
HPV INFECTIONS WITH RECENT ADVANCES IN CARCINOMA CERVIX.pptx
Mission SAY No to Cervical Cancer With HPV Vaccination DR. SHARDA JAIN S...
Mission SAY No to Cervical Cancer With HPV Vaccination DR. SHARDA JAIN S...
Cervical cancer screening guidelines 2013 on 7th sept
Cervical cancer screening guidelines 2013 on 7th sept
AN OPPORTUNITY FOR HPV VACCINATION , Dr. Sharda Jain Lifecare Centre
AN OPPORTUNITY FOR HPV VACCINATION , Dr. Sharda Jain Lifecare Centre
Vulvar and vaginal cancer epidemiology and molecular pathogenesis
Vulvar and vaginal cancer epidemiology and molecular pathogenesis
Recently uploaded
Test bank clinical nursing skills a concept based approach 4e pearson educati...
Test bank clinical nursing skills a concept based approach 4e pearson educati...rightmanforbloodline
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson educationLuxury Massage Experience at Affordable Rate - Malayali Kerala Spa Ajman
At Malayali Kerala Spa Ajman we providing the top quality massage services for our customers.
Our massage center prioritizes efficiency to ensure a quality massage experience for our clients at Malayali Kerala Spa Ajman. We offer a convenient appointment system and precise massage services.
Reach us at Villa No 7, Near Ammar Bin Yasir Street Al Rashidiya 2 - Ajman - United Arab Emirates.
Phone : +971 529818279
Columbia毕业证书退学办理
哥伦比亚大学毕业证成绩单(留信网认证)【176555708微信】24小时办理学位证书编号怎么查
Columbia文凭毕业证学位证（176555708微信）加急制作哥伦比亚大学毕业证认证成绩单密封邮寄|Columbia研究生毕业证书学位证书|哥伦比亚大学Office Transcript美国I20修改|Columbia Office Transcript diploma 学历认证
Columbia毕业证【微信176555708】哥伦比亚大学毕业证书原版↑制作哥伦比亚大学学历认证文凭办理哥伦比亚大学留信网认证,留学回国办理毕业证成绩单文凭学历认证【微信176555708】专业为海外学子办理毕业证成绩单、文凭制作，学历仿制，回国人员证明、做文凭，研究生、本科、硕士学历认证、留信认证、结业证、学位证书样本、美国教育部认证百分百真实存档可查】
The Ultimate Guide in Setting Up Market Research System in Health-Tech
How to effectively start market research in the health tech industry by defining objectives, crafting problem statements, selecting methods, identifying data collection sources, and setting clear timelines. This guide covers all the preliminary steps needed to lay a strong foundation for your research.
"Market Research it too text-booky, I am in the market for a decade, I am living research book" this is what the founder I met on the event claimed, few of my colleagues rolled their eyes. Its true that one cannot over look the real life experience, but one cannot out beat structured gold mine of market research.
Many 0 to 1 startup founders often overlook market research, but this critical step can make or break a venture, especially in health tech.
But Why do they skip it?
Limited resources—time, money, and manpower—are common culprits.
"In fact, a survey by CB Insights found that 42% of startups fail due to no market need, which is like building a spaceship to Mars only to realise you forgot the fuel."
Sudharsan Srinivasan
Operational Partner Pitchworks VC Studio
Overconfidence in their product’s success leads founders to assume it will naturally find its market, especially in health tech where patient needs, entire system issues and regulatory requirements are as complex as trying to perform brain surgery with a butter knife. Additionally, the pressure to launch quickly and the belief in their own intuition further contribute to this oversight. Yet, thorough market research in health tech could be the key to transforming a startup's vision into a life-saving reality, instead of a medical mishap waiting to happen.
Example of Market Research working
Innovaccer, founded by Abhinav Shashank in 2014, focuses on improving healthcare delivery through data-driven insights and interoperability solutions. Before launching their platform, Innovaccer conducted extensive market research to understand the challenges faced by healthcare organizations and the potential for innovation in healthcare IT.
Identifying Pain Points: Innovaccer surveyed healthcare providers to understand their difficulties with data integration, care coordination, and patient engagement. They found widespread frustration with siloed systems and inefficient workflows.
Competitive Analysis: Analyzed competitors offering similar solutions in healthcare analytics and interoperability. Identified gaps in comprehensive data aggregation, real-time analytics, and actionable insights.
Regulatory Compliance: Ensured their platform complied with HIPAA and other healthcare data privacy regulations. This compliance was crucial to gaining trust from healthcare providers wary of data security issues.
Customer Validation: Conducted pilot programs with several healthcare organizations to validate the platform's effectiveness in improving care outcomes and operational efficiency. Gathered feedback to refine features and user interface.
Correlation between surface motion and heart-breast distance for breast cance...
Lisa Dietrich,
MSc, Medical physicist in training and PhD candidate
Universitätsklinikum Erlangen
Germany
05 CLINICAL AUDIT-ORTHO done at a peripheral.pptx
Clinical audit on pain management done at peripheral health centre
Kolkata Call Girls 🔝 7374876321 🔝 Top Escorts Service Experiences With Fore...
Kolkata Call Girls 🔝 7374876321 🔝 Top Escorts Service Experiences With Foreignerj11
EXAMINATION OF HUMAN URINE AND FAECES.pdf
This presentation will help to develop in-depth knowledge of the examination of Urine and Faeces.
Test bank calculating drug dosages a patient safe approach to nursing and mat...
Test bank calculating drug dosages a patient safe approach to nursing and mat...rightmanforbloodline
Test bank calculating drug dosages a patient safe approach to nursing and math 2nd edition by castillo werner mccullough
Test bank calculating drug dosages a patient safe approach to nursing and math 2nd edition by castillo werner mccullough
Test bank calculating drug dosages a patient safe approach to nursing and math 2nd edition by castillo werner mcculloughAbout CentiUP - Introduction and Products.pdf
A heightened child formula, with the trio of Nano Calcium, HMO, and DHA mixed in the golden ratio, combined with NANO technology to help nourish the body deeply and comprehensively, helps children increase height, boost brain power, and improve the immune system and overall well-being.
PPT on Embryological and fetal development
Embryological development and fetal development
Factors influencing fetal development
Nursing management of the patient with Tonsillitis PPT
Prepared by Prof. Blessy Thomas MSc Nursing, FNCON, SPN. The tonsils are two small glands that sit on either side of the throat.
In young children, they help to fight germs and act as a barrier against infection.
Tonsils act as filters, trapping germs that could otherwise enter the airways and cause infection.
They also make antibodies to fight infection.
But sometimes, they get overwhelmed by bacteria or viruses.
This can make them swollen and inflamed.
Tonsillitis is an infection of the tonsils, two masses of tissue at the back of the throat.
Tonsillitis is inflammation of the tonsils, two oval-shaped pads of tissue at the back of the throat — one tonsil on each side.
Tonsillitis is common, especially in children.
It can happen once in a while or come back again and again in a short period.Nursing management of Tonsillitis is important.
A comprehensive understanding of the operations for management of Tonsillitis and areas requiring special attention would be important.
Call Girls Goa 7023059433 Celebrity Escorts Service in Goa
Call Girls Goa 7023059433 Celebrity Escorts Service in Goa
Recently uploaded (20)
Test bank clinical nursing skills a concept based approach 4e pearson educati...
Test bank clinical nursing skills a concept based approach 4e pearson educati...
Luxury Massage Experience at Affordable Rate - Malayali Kerala Spa Ajman
Luxury Massage Experience at Affordable Rate - Malayali Kerala Spa Ajman
The Ultimate Guide in Setting Up Market Research System in Health-Tech
The Ultimate Guide in Setting Up Market Research System in Health-Tech
HEALTH ASSESSMENT IN NURSING USING THE NURSING PROCESSpptx
HEALTH ASSESSMENT IN NURSING USING THE NURSING PROCESSpptx
Correlation between surface motion and heart-breast distance for breast cance...
Correlation between surface motion and heart-breast distance for breast cance...
Kolkata Call Girls 🔝 7374876321 🔝 Top Escorts Service Experiences With Fore...
Kolkata Call Girls 🔝 7374876321 🔝 Top Escorts Service Experiences With Fore...
Test bank calculating drug dosages a patient safe approach to nursing and mat...
Test bank calculating drug dosages a patient safe approach to nursing and mat...
Nursing management of the patient with Tonsillitis PPT
Nursing management of the patient with Tonsillitis PPT
Call Girls Goa 7023059433 Celebrity Escorts Service in Goa
Call Girls Goa 7023059433 Celebrity Escorts Service in Goa
Adopting new technologies for cervical cancer prevention
- 1. ADOPTING NEW TECHNOLOGIES FOR CERVICAL CANCER PREVENTION
- 2. DISEASE PROGRESSION 2 WE CAN IDENTITY WOMEN AT RISK OF CERVICAL CANCER BEFORE IT DEVELOPS 5 – 10 years Vaccination HPV Testing Cytology and VIA Colposcopy 5-10 years from infection to cancer
- 3. IMPACT OF 70% VACCINE COVERAGE OF WOMEN ON CERVICAL CANCER DEATHS 3 PRIMARY PREVENTION 0 2 4 6 8 10 12 14 -10 0 10 20 30 40 50 TIME SINCE INTRODUCTION OF VACCINE (YEARS) CERVICALCANCERDEATHS (PER100,000PERYEAR) WHO estimate the number of women with Cervical cancer will double by 2020, even with vaccination
- 4. SECONDARY PREVENTION: HPV TESTING 4 TECHNOLOGY Screen with HPV Molecular Test Triage with Cytology Diagnose with Colposcopy or Histology Treat VaccinateYoung Girls • Detects existing infection – the cause of the disease • Identifies women at risk of cervical disease for earlier treatment • Used on women aged 30< • Test every 3-5 years
- 5. WHY HPV DNA/RNA TESTING? 5 • Is more sensitive than cytology or VIA • Detects lesions earlier for treatment • Is a better predictor of risk for developing cancer • Detects clinically relevant levels of HPV DNA and sub-types • Provides longer term protection of 7+ years • Cost effective - standardized, objective • Self collection option - to extend coverage Key Findings • Reduction in cervical cancer • Improved management of patients • Objectivity – not dependent on human interpretation • Turnaround time – results in 1 day • Opportunity to automate • Opportunity to add self-sampling to increase coverage Benefits • Almost 100% protection from a deadly disease • Single visit for HPV and cytology • Possibility to take her own sample Patients Benefits SAFETY, REASSURANCE AND CONVENIENCE
- 6. PREVENTION STRATEGY 6 WORKING TOGETHER TO CREATE A CANCER FREE WORLD Vaccinatio n Improved Screening 100% Protection